✨ Your Portfolio is fetched and updated from zerodha.
Micro Pharmaceuticals

Bharat Immunologicals & Biologicals Corporation Ltd.

BIBCL

Market Cap
₹106 Cr.
P/E
0.00

Bharat Immunologicals & Biologicals Corporation Ltd.

  • Bharat Immunological
  • Ind-Swift
  • Makers Laboratories
FAQs on Bharat Immunologicals & Biologicals Corporation Ltd. Shareprice

Bharat Immunological has given lower returns compared to its competitors.
Bharat Immunological has grown at ~3.05% over the last 2yrs while peers have grown at a median rate of 10.06%

There is insufficient historical data to gauge this.
Latest PE of Bharat Immunological is 0

View FAQ's On Business
Growth Table
  • Bharat Immunologicals & Biologicals Corporation Ltd.
  • Ind-Swift
  • Makers Laboratories
Balance Sheet
  • Bharat Immunologicals & Biologicals Corporation Ltd.
  • Ind-Swift
  • Makers Laboratories
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Bharat Immunologicals & Biologicals Corporation Ltd.
  • Ind-Swift
  • Makers Laboratories
Cash Flow
  • Bharat Immunologicals & Biologicals Corporation Ltd.
  • Ind-Swift
  • Makers Laboratories
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Bharat Immunologicals & Biologicals Corporation Ltd.
  • Ind-Swift
  • Makers Laboratories
Quarterly Results
  • Bharat Immunologicals & Biologicals Corporation Ltd.
  • Ind-Swift
  • Makers Laboratories
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF
FAQs on Bharat Immunologicals & Biologicals Corporation Ltd. Financials

Bharat Immunological balance sheet is weak and might have solvency issues

Yes, The net debt of Bharat Immunological is increasing.
Latest net debt of Bharat Immunological is ₹65.45 Crs as of Sep-23.
This is greater than Mar-23 when it was ₹52.75 Crs.

No, profit is decreasing.
The profit of Bharat Immunological is -₹17.27 Crs for TTM, -₹16.64 Crs for Mar 2023 and -₹8.75 Crs for Mar 2022.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Bharat Immunological latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech